Insights Into Sequencing Treatment and Overcoming Resistance in HR-Positive/HER2-Negative ABC

Get up to date on optimal management of HR-positive/HER2-negative advanced breast cancer by watching the on-demand Webcast and downloading slides from a dynamic expert presentation on current and emerging therapies targeting CDK4/6 PI3K AKT mTOR and more!

Share

Program Content

Activities

HR+/HER2- ABC: Webcast
Insights Into Sequencing Treatment and Overcoming Resistance in HR-Positive/HER2-Negative ABC
Congratulations: You achieved a completion on 04/09/2022

Activities

<i>EP:</i> HR+/HER2- ABC
ExpressPoints: Sequencing Treatment and Overcoming Resistance in HR-Positive/HER2-Negative ABC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 01, 2020

Expires: June 30, 2021

CDK4/6i for HR+/HER2- ABC
CDK4/6 Inhibitors for Premenopausal and Postmenopausal Women With HR-Positive/HER2-Negative Advanced Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2020

Expires: June 16, 2021

PI3K/AKT/mTORi for ABC
PI3K/AKT/mTOR Inhibitors and Future Directions in HR+/HER2- Advanced Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2020

Expires: June 16, 2021

Faculty

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Lilly